Evidence map›Paper›PMID 34729614›Full record

ArticleSouthern medical journal2021

Initial Institutional Experience with 18F-Fluciclovine PET-CT in Biochemical Recurrence of Prostate Cancer.

Amy B Farkas, Edward D Green, Anson L Thaggard, Vani Vijayakumar, John C Henegan, Seth T Lirette, Mary R Nittala, Srinivasan Vijayakumar

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Southern medical journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Application of Metabolic Reprogramming to Cancer Imaging and Diagnosis.International journal of molecular sciences · 2022
    Review
  2. [Cancers · 2022
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Amy B FarkasFrom the Departments of Radiology, Hematology/Oncology, Data Science, and Radiation Oncology, University of Mississippi Medical Center, Jackson.
Edward D GreenFrom the Departments of Radiology, Hematology/Oncology, Data Science, and Radiation Oncology, University of Mississippi Medical Center, Jackson.
Anson L ThaggardFrom the Departments of Radiology, Hematology/Oncology, Data Science, and Radiation Oncology, University of Mississippi Medical Center, Jackson.
Vani VijayakumarFrom the Departments of Radiology, Hematology/Oncology, Data Science, and Radiation Oncology, University of Mississippi Medical Center, Jackson.
John C HeneganFrom the Departments of Radiology, Hematology/Oncology, Data Science, and Radiation Oncology, University of Mississippi Medical Center, Jackson.
Seth T LiretteFrom the Departments of Radiology, Hematology/Oncology, Data Science, and Radiation Oncology, University of Mississippi Medical Center, Jackson.
Mary R NittalaFrom the Departments of Radiology, Hematology/Oncology, Data Science, and Radiation Oncology, University of Mississippi Medical Center, Jackson.
Srinivasan VijayakumarFrom the Departments of Radiology, Hematology/Oncology, Data Science, and Radiation Oncology, University of Mississippi Medical Center, Jackson.
University of Mississippi Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectives18F-fluciclovine (fluciclovine) is an amino acid analog approved by the Food and Drug Administration for use as a radiotracer in positron emission tomography (PET) in men with biochemical recurrence of suspected prostate cancer. The purpose of this study was to investigate the initial institutional experience with 18F-fluciclovine in the evaluation of prostate cancer with biochemical recurrence.

methodsThis study was a retrospective review of 135 patients who underwent 18F-fluciclovine PET-computed tomography (PET-CT) at a single institution from August 2018 through January 2020. Prognostic information, including prostate-specific level antigen (PSA) at the time of diagnosis, initial risk, initial Gleason score, and initial stage, was reviewed as well as the PSA level at the time of the scan. The images were reviewed by two radiologists with fellowship training in nuclear medicine and additional training to interpret the fluciclovine studies. A minority of studies were reviewed by a third fellowship-trained radiologist under the guidance of the two nuclear medicine-trained radiologists. In cases with abnormal radiopharmaceutical uptake in lymph nodes, the short-axis dimension of the lymph node or largest lymph node with abnormal uptake was noted. If CT or bone scan was performed within 4 months of the 18F-fluciclovine PET-CT, findings on the alternate imaging were compared with the results of the 18F-fluciclovine PET-CT.

resultsOur institutional positivity rate was 75.6%, with 64 (67.4%) patients with metastatic disease and 71 (52.6%) patients with local recurrence detected by fluciclovine. As expected, the rate of positive examinations increased with increasing PSA values measured at the time of imaging (

conclusionsOur single-institution experience with 18F-fluciclovine PET-CT has the largest number of patients to date in the literature and demonstrates the ability of fluciclovine to help guide clinical management in the detection of early recurrent disease.

Indexed as

AgedCarboxylic AcidsCyclobutanesHumansMaleMiddle AgedPositron Emission Tomography Computed TomographyProstatic NeoplasmsRecurrenceRetrospective StudiesCarboxylic AcidsCyclobutanesfluciclovine F-18

Identifiers

PMID34729614
PMCPMC8560157
OpenAlexW3210218323

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.